| 1 |
Liu SR, Yan Q, Lin HM, Shi GZ, Cao Y, Zeng H, Liu C, Zhang R. Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports. World J Clin Cases 2021; 9(21): 5988-5998 [PMID: 34368318 DOI: 10.12998/wjcc.v9.i21.5988] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 2 |
Liu J, Zhang SQ, Chen J, Li ZB, Chen JX, Lu QQ, Han YS, Dai W, Xie C, Li JC. Identifying Prognostic Significance of RCL1 and Four-Gene Signature as Novel Potential Biomarkers in HCC Patients. J Oncol 2021;2021:5574150. [PMID: 34257652 DOI: 10.1155/2021/5574150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 4 |
Sheth N, Osborn V, Lee A, Schreiber D. Stereotactic Ablative Radiotherapy Fractionation for Hepatocellular Carcinoma in the United States. Cureus. 2020;12:e8675. [PMID: 32699675 DOI: 10.7759/cureus.8675] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 5 |
Bajwa R, Madoff DC, Kishore SA. Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions. Dig Dis Interv 2020;4:134-47. [PMID: 32832829 DOI: 10.1055/s-0040-1712146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 6 |
Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers (Basel) 2020;12:E791. [PMID: 32224882 DOI: 10.3390/cancers12040791] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 7 |
Abdel-Rahman O, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2020;1:CD011313. [PMID: 31978267 DOI: 10.1002/14651858.CD011313.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Kovács A, Iezzi R, Cellini F, Lancellotta V, Bischoff P, Carchesio F, Tagliaferri L, Kovács G, Gambacorta MA. Critical review of multidisciplinary non-surgical local interventional ablation techniques in primary or secondary liver malignancies. J Contemp Brachytherapy 2019;11:589-600. [PMID: 31969919 DOI: 10.5114/jcb.2019.90466] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 9 |
Zubiri L, Bilbao JI, Rodríguez J, Sangro B. Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors. Hepat Oncol 2018;5:HEP09. [PMID: 31293777 DOI: 10.2217/hep-2017-0025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 10 |
Toesca DAS, Ibragimov B, Koong AJ, Xing L, Koong AC, Chang DT. Strategies for prediction and mitigation of radiation-induced liver toxicity. J Radiat Res 2018;59:i40-9. [PMID: 29432550 DOI: 10.1093/jrr/rrx104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 11 |
Abdel-Rahman O, Cheung WY. The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:4763832. [PMID: 30159302 DOI: 10.1155/2018/4763832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 12 |
Lyadov KV, Kaprin AD, Rerberg AG, Kozyrin IA, Lyadov VK, Maiorov KV, Kaprin DA, Moroz OV, Cherednichenko DV, Dobreva IY, Polushkin VG, Khodovsky AA. Therapy for inoperable hepatocellular carcinoma with selective transarterial radioembolization with yttrium-90 microspheres. Onkol Z im P A Gercena 2018;7:55. [DOI: 10.17116/onkolog20187355] [Reference Citation Analysis]
|
| 13 |
Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 196] [Cited by in F6Publishing: 222] [Article Influence: 32.7] [Reference Citation Analysis]
|
| 14 |
Mu L, Chapiro J, Stringam J, Geschwind JF. Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation. Cancer J 2016;22:365-72. [PMID: 27870678 DOI: 10.1097/PPO.0000000000000227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 15 |
Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma: An attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011650. [PMID: 28351116 DOI: 10.1002/14651858.cd011650.pub2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 16 |
Abdel-Rahman O, Elsayed Z. External beam radiotherapy for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2017;3:CD011314. [PMID: 28267205 DOI: 10.1002/14651858.CD011314.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 17 |
Gebski V, Gibbs E, Gandhi M, Chatellier G, Dinut A, Pereira H, Chow PK, Vilgrain V. VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. JMIR Res Protoc 2017;6:e17. [PMID: 28202430 DOI: 10.2196/resprot.7016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 18 |
Bornschein J, Schlosser S, Schreyer AG, Müller-schilling M. Das hepatozelluläre Karzinom. Gastroenterologe 2016;11:368-382. [DOI: 10.1007/s11377-016-0101-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
